Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome.

[1]  F. Mellot,et al.  Sustained response to mepolizumab in refractory Churg-Strauss syndrome. , 2010, The Journal of allergy and clinical immunology.

[2]  Parameswaran Nair,et al.  Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.

[3]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[4]  Yoshiyuki Yamada,et al.  Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. , 2008, The Journal of allergy and clinical immunology.

[5]  J. Parkin,et al.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab. , 2008, The New England journal of medicine.

[6]  W. Busse,et al.  A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.

[7]  A. Buist,et al.  Asthma drug use and the development of Churg–Strauss syndrome (CSS) , 2007, Pharmacoepidemiology and drug safety.

[8]  M. Collins,et al.  Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. , 2006, The Journal of allergy and clinical immunology.

[9]  B. Hellmich,et al.  Proinflammatory Cytokines and Autoimmunity in Churg‐Strauss Syndrome , 2005, Annals of the New York Academy of Sciences.

[10]  J. Ring,et al.  Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. , 2003, The New England journal of medicine.

[11]  D. Postma,et al.  Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. , 2003, American journal of respiratory and critical care medicine.

[12]  J. Denburg,et al.  Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. , 2003, The Journal of allergy and clinical immunology.

[13]  A. Kay,et al.  Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. , 2003, American journal of respiratory and critical care medicine.

[14]  M. J. Leckie.  Anti-Interleukin-5 Monoclonal Antibodies , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.

[15]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[16]  R. Williams,et al.  Churg-Strauss syndrome: localization of eosinophil major basic protein in damaged tissues. , 2000, Arthritis and rheumatism.

[17]  C. Davis,et al.  Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. , 1999, The Journal of pharmacology and experimental therapeutics.

[18]  G H Guyatt,et al.  Development and validation of a questionnaire to measure asthma control. , 1999, The European respiratory journal.

[19]  J. Even,et al.  Involvement of soluble CD95 in Churg-Strauss syndrome. , 1999, The American journal of pathology.

[20]  W. Gross,et al.  Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome , 1999, Thorax.

[21]  R. Mann,et al.  Prevalence of Churg–Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription‐event monitoring cohort studies , 1999, Pharmacoepidemiology and drug safety.

[22]  M. Isobe,et al.  Eosinophil active cytokines and surface analysis of eosinophils in Churg-Strauss syndrome. , 1999, Allergy and asthma proceedings.

[23]  M. Jordana,et al.  Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia. , 1998, The Journal of clinical investigation.

[24]  R. Moots,et al.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. , 1994, QJM : monthly journal of the Association of Physicians.

[25]  C. Sanderson.  Interleukin-5, Eosinophils, and Disease , 1992 .

[26]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). , 2010, Arthritis and rheumatism.

[27]  M. Strath,et al.  Eosinophilia in transgenic mice expressing interleukin 5 , 1990, The Journal of experimental medicine.